Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Greimel, E; Kristensen, GB; van der Burg, ME; Coronado, P; Rustin, G; del Rio, AS; Reed, NS; Nordal, RR; Coens, C; Vergote, I; European Organization for Research and Treatment of Cancer - Gynaecological Cancer Group and NCIC Clinical Trials Group.
Quality of life of advanced ovarian cancer patients in the randomized phase III study comparing primary debulking surgery versus neo-adjuvant chemotherapy.
Gynecol Oncol. 2013; 131(2):437-444
Doi: 10.1016/j.ygyno.2013.08.014
Web of Science
PubMed
FullText
FullText_MUG
- Führende Autor*innen der Med Uni Graz
- Greimel Elfriede Renate
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Objective. The EORTC 55971 trial compared primary debulking surgery (PDS) versus neo-adjuvant chemotherapy (NACT) followed by interval debulking surgery (IDS). The impact of both treatment arms on quality of life (QOL) is reported. Methods. Patients with stages IIIc or IV ovarian cancer completed the EORTC QLQ-C30 before treatment, at the third and sixth cycle of chemotherapy, and at 6- and 12-month follow-up. Results. Data of 404 patients (N = 201 PDS arm; N = 203 IDS arm) were included in the QOL analysis. Between treatment arms no statistically significant differences were found in any of the QOL functioning scales. Patients showed a clinically relevant improvement (>10 points) on the global health/QOL, role functioning, emotional functioning and social functioning scales during and after treatment independent of the type of treatment. Clinically relevant differences from baseline to the follow-up assessments were noted for fatigue, pain, insomnia, appetite loss, constipation, diarrhea indicating symptom control in both treatment arms. Institutions with good QOL compliance were associated with better outcomes. There was a statistical significant difference in the overall debulldng status with 39.9% optimal debulking surgery in institutions with good QOL compliance compared to 19.9% in institutions with poor QOL compliance (p = 0.0011). Overall survival (median 32.30 versus 23.29 months; p = 0.0006) and progression free survival (median 12.35 versus 9.92 months; p = 0.0002) were also significantly better. Conclusions. Survival and QOL after NACT followed by surgery was similar to survival and QOL after PDS followed by chemotherapy. However, institutions with good QOL compliance had better survival outcomes. (C) 2013 Elsevier Inc. All rights reserved.
- Find related publications in this database (using NLM MeSH Indexing)
- Adult -
- Aged -
- Aged, 80 and over -
- Antineoplastic Combined Chemotherapy Protocols - therapeutic use
- Chemotherapy, Adjuvant -
- Disease-Free Survival -
- Female -
- Humans -
- Middle Aged -
- Neoadjuvant Therapy -
- Neoplasm Staging -
- Neoplasms, Glandular and Epithelial - drug therapy
- Organoplatinum Compounds - administration & dosage
- Ovarian Neoplasms - drug therapy
- Quality of Life -
- Survival Rate -
- Find related publications in this database (Keywords)
- Ovarian cancer
- Quality of life
- Patient-reported outcomes
- Phase III trial
- Gynecologic oncology